New long-term data reinforce safety profile of Pradaxa® for stroke prevention in AF
New long-term data from the RELY-ABLE® study...
17 June 2013 | By Boehringer Ingelheim
New long-term data from the RELY-ABLE® study...
List view / Grid view
New long-term data from the RELY-ABLE® study...
17 June 2013 | By Boehringer Ingelheim
New long-term data from the RELY-ABLE® study...
Pivotal data from the RELY-ABLE® study have provided additional data...
8 November 2012 | By Boehringer Ingelheim
Pivotal data from the RELY-ABLE® study have provided additional data...
A new analysis of the 18,113 patient...
18 April 2012 | By Boehringer Ingelheim
A new analysis of the 18,113 patient...
Pradaxa®1 (dabigatran etexilate) approved...
4 August 2011 | By Ogilvy Healthworld UK Limited
Pradaxa®1 (dabigatran etexilate) approved...
Sanofi announced that the company has discontinued the PALLAS Phase…
7 July 2011 | By Sanofi
Sanofi announced that the company has discontinued the PALLAS Phase IIIb trial...
Bristol-Myers Squibb Company and Pfizer Inc. announce the publication of…
10 February 2011 | By Pfizer
Bristol-Myers Squibb Company and Pfizer Inc. announce the publication of their AVERROES study of apixaban in The New England Journal of Medicine...